Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (January 2020)
20 slides from Bioxytran's investor presentation, Jan 31, 2020
Slide 1: BioXyTran, Inc. – Tissue Regeneration For Life
Slide 2: Mission Statement
MISSION STATEMENT BioxyTran’s mission is to develop effective drug treatments for hypoxia (oxygen deficiency) which delivers oxygen to tissues with the potential to improve a myriad of medical conditions. Bio.XyTran....
Slide 3: Defeating the Outbreak – A Simple Plan
Bio.XyTran.. Defeating the Outbreak — A Simple Plan — Time a luxury we don’t have Use of Virus Drugs Distribution of drugs a real challenge in uncontrolled settings. Measuring efficacy is impossible without a device to measure tissue health. QO) Containing the disease takes time QO) Developing a vac
Slide 4: The Problem – Tissue Oxygenation for Severe Respiratory Distress Syndrome
The Problem — Tissue Oxygenation for Severe Respiratory Distress Syndrome BioXyTran.. a el Late Stage Corona and Influenza virus patients develop fluid in their lungs A respirator forces the liquid level in alveoli sacks down so blood can get closer to the oxygen (Not very effective) The blood is ph
Slide 5: BXT-25 Solution for Severe Respiratory Distress Syndrome (SRDS)
BXT-25 Solution for Severe Respiratory Distress Syndrome (SRDS) - Restores oxygen the same way as red blood cells - Results show no known side effects - Delivers viable treatment continuously - Increase tissue oxygenation regardless of fluid levels in the lungs ———, BioXyTran..
Slide 6: When Two Scientists' Research Collide
BioXyTran.. When Two Scientist's Research Collide wag aK A A! 30 Years Researching Hypoxia Major Scientific Nobel Prize — Study of Hypoxia 30 Patents Validation 10 Journal Articles 2 Textbooks ; Embraced by Scientific 90 Years Since the Last Breakthrough in 5 Public Companies & Medical Minds the Stu
Slide 7: Theory of the Cellular Universe
Bio.XyTran.. ~~ Theory of the Cellular Universe This is the E=mc2 for cells Delivering Oxygen to Tissues Reduces Hypoxia: Reduced Hypoxia Improves the Condition of Tissues = Prolyl Proteasomal i degradation Theory Predicts Cellular Interaction within the Tissue Micro-Environment Hypoxia XM https://w
Slide 8: BXT-25 Optimizes the Efficacy of Prior Technology
BXT-25 Optimizes the Efficacy of Prior Technology BioXyTran.. eee §=HemoPure @ 100 Years Research @ $460MM in R&D @ 400 Peer Reviewed Articles @ 27 Clinical Trials @ 830 Patients Dosed @ 2 Animal Studies @ 510(K) Approval @ Approved in South Africa, Russia & U.S. (Veterinary) @ Carbohydrate Binding
Slide 9: Expected Safety Profile of the Drug BXT-25
Bio,XyTran.. Expected Safety Profile of the Drug BXT-25 a BioxyTran Combines Heme with a Co-Polymer Heme: An FDA approved material Co-polymer: FDA Approved sugar that identifies and delivers oxygen stabilizes Heme in blood and similar to red blood cells eliminates nitric oxide scavenging BXT-25's un
Slide 10: BioxyTran Has Developed an Oxygen Transport Molecule: BXT-25
BioXyTran: . BioxyTran Has Developed an Oxygen Transport Molecule: BXT-25 ~~ Universal Challenge: Delivering oxygen to ischemic tissues and measuring the effect of increased oxygen levels Heme Hemoglobin Erythrocyte Solution: Separating HEME from GLOBIN - Create molecule 5000 times smaller than a re
Slide 11: Clinical Unmet Need
BioXyTran.. Clinical Unmet Need NL Oxygen level (mmHg) Compartment Monitored Parameter Atmospheric Air 160 21% O, in Air Systemic Vital Signs Respiratory Rate & Volume Respiratory System 100 End-Tidal CO, (ET-CO,) Heart Rate (HR) Electrocardiogram (ECG) Cardiac Output (CO) 95 Systemic Blood Pressure
Slide 12: Mitochondrial NADH/Fp Redox State
Mitochondrial NADH/Fp Redox State Conversion of Glucose to ATP Glycolysis Glucose ————» Pyruvic Acid VA. onic Homeostasis. Wf 2. Signal Conduction 3, Muscle contraction 4. Glandular Secretion Mitochondrial 5. G4 tract and kidney ene ene Demand NADHIFp Redox State Tissve Oxygen (Energy Balance \ BioX
Slide 13: MDX Monitoring for Severe Respiratory Distress Syndrome
FaSinor nee Mitochondrial Function Doswler (Frequency) Shi Photoplethysmographic analysis § Arterial pressure sams) e 2 Parameters: 1. Pulse oximetry 2. Heart rate MDX Monitoring for Severe Respiratory Distress Syndrome (SRDS) FDA Approved a B. : Light Source Unit Detection Unit BioXyTran..
Slide 14: Competitive Environment
Competitive Environment Systemic Monitoring Specific Monitoring “._ Organ/System Monitored Parameter Systemic Vital Signs Respiratory System Respiratory Rate & Volume End-Tidal CO, (ET-CO,) Cardiovascular System Heart Rate (HR) Electrocardiogram (ECG) Cardiac Output (CO) Systemic Blood Pressure (BP)
Slide 15: The Effective Treatment of Hypoxia Addresses Many Medical Conditions
< AGING2?COPD’ = CANCER PNEUMONIA w Cystic Fibrosis .2 - ~m PSORIASIS £ Broncuitis © PULMONARY EDEMA v 'S DISEA . = STROKE joiasetes « - Pheumatoid Arthritis ECZEMA © = Crohn's Disease = ULCERATIVE COLITIS = Sratune = LIVER FIBROSIS AND CIRRHOSIS |“ LLJ HEART ATTACK inFtammatory BOWEL DISEASE 7) = <
Slide 16: Strategy for Successful Commercialization of BXT-25
Bio.XyTran.. Strategy for Successful Commercialization of BXT-25 — * Pursue functional claim of tissue oxygenation * Finalize development of MDX Viewer —_ LICENSING DEAL * Prioritize stroke application in near term * Explore a myriad of other applications/treatments * Build core team to scale future
Slide 17: Big Pharma Licensing Opportunities for BXT-25
Big Pharma Licensing Opportunities for BXT-25 = | "°"™" Oncology Respiratory Neuroscience Hematology Immunology Inflammation Cardiovascular Stroke Oncology Neuroscience Immunology Cardiovascular Oncology Neuroscience Immunology Hematology Oncology Neuroscience Cardiovascular — Oncology Neuroscience
Slide 18: Use of Proceeds from Equity Private Placement
Use of Proceeds from Equity Private Placement wpe $2.5 million Manufacturing CMC Preclinical: (two species: rats and dogs) $0.5million Clinical Trials $3.0 million SG&A Expense $2.5 million MDX licensing transaction $1.5 million Total $10.0 Million
Slide 19: Leadership
Leadership David Platt, Ph.D/CEO Ph.D in Chemical Engineering, Hebrew University of Jerusalem; Weizmann Institute; Founder of five public Bio-Tech companies over a 25-year period with a combined market capitalization of more than $1.5 billion Elena Chekhova, Ph.D/Chief Scientist Ph.D in Process Syst
Slide 20: BioXyTran, Inc. contact details
BioXyTran, Inc. 233 Needham St., Suite 300 Newton MA, 02464 (617)-454-1199 www.bioxytraninc.com David Platt david.platt@bioxytraninc.com (617)-510-2539